Skyhawk Therapeutics was founded in 2016 by Bill Haney and Kathleen McCarthy. Maura McCarthy, vice president of corporate development told reporters in 2021 that the company was likely to go public in the next 12 to 18 months, and that a $130 million fundraising round would be the last private fundraise before the company went public. The company remains private as of June 2023.
Skyhawk is a biotechnology company using its SkySTAR RNA splicing platform to develop new, small molecule drugs. The company has raised more than $600 million in venture capital and partnership funding. Investors include Fidelity Management & Research Company, Alexandria Venture Investments, GreatPoint Ventures, ShangPharma Innovation, and Agent Capital. Additionally, as of June 2023, the company maintains strategic partnerships with Bristol Myers Squibb, Merck & Co., and Vertex Pharmaceuticals. Skyhawk did not disclose valuation figures following a $133 million funding round in 2021.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Skyhawk Therapeutics is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
Skyhawk Therapeutics has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
Skyhawk Therapeutics is privately held company and is not publicly traded, therefor investing in Skyhawk Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.
To determine the value of your Skyhawk Therapeutics shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Skyhawk Therapeutics shares. You can also learn more about how to sell your private shares before getting started.
Yes, you can seek to sell shares in Skyhawk Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.